We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Advanced Mass Spectrometry Could Provide Microscopic Clues to Beating Deadly Brain Tumors

By LabMedica International staff writers
Posted on 01 Nov 2022

Glioblastoma is one of the most difficult cancers, let alone diseases, to treat. More...

The brain tumor presents a median survival rate of just 12 to 15 months. The cancer is especially hard to beat, since it presents so heterogeneously – with different tumor cell subtypes within the same tumor, which can all respond differently to therapy. The cancer also has a tendency to create aberrant small blood vessel networks quickly, helping it spread quickly – and making it particularly hard to defeat through traditional treatment pathways. Now, scientists have discovered that a critical new pathway to treating glioblastoma might be found in the complex diversity within the tumor tissue.

A team of scientists at the Hackensack Meridian Center for Discovery and Innovation (CDI, Nutley, NJ, USA) deeply analyzed tumor tissue using an advanced mass spectrometry with special focus on lipids, a class of molecules that includes fats. The scientists assessed five human samples of brain tumor tissue. The team looked at a series of different lipids, in different sections of the tumor and the surrounding environment, and found a series of possible treatment candidates.

“Lipid ions presented here lay the foundation for future studies that are required to understand their interconnecting signaling pathways in relation to cell function, tumor progression, and resistance to therapy,” according to the paper. “Understanding their functional relevance is essential for the identification of new therapeutics based on lipid pathway targets.”

“In conclusion, high resolution MALDI MSI identified a number of lipids that differentiate tumor and endothelial cell subpopulations within human glioblastoma samples,” the authors write. “The heterogenous distributions… within these cell population further highlight the complexity of the glioblastoma TME.”

The scientists hypothesize that a multi-pronged approach may fare best against the stubborn cancer.

“Targeting several of these lipids and their signaling pathways simultaneously, however, may improve clinical outcome,” they write.

Related Links:
CDI


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Collection and Transport System
PurSafe Plus®
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
New
Gold Member
Hybrid Pipette
SWITCH
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: When assessing the same lung biopsy sample, research shows that only 18% of pathologists will agree on a TCMR diagnosis (Photo courtesy of Thermo Fisher)

Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection

Lung transplant recipients face a significant risk of rejection and often require routine biopsies to monitor graft health, yet assessing the same biopsy sample can be highly inconsistent among pathologists.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.